Discussion

0 comments

Be the first to call it.

Resolution

Rule

This market resolves YES to exactly one child — the first US retailer or pharmacy chain to publicly launch a private-label GLP-1 program in 2026. 'Private-label GLP-1 program' is defined as: the retailer selling a GLP-1 medication (semaglutide, tirzepatide, liraglutide, or equivalent) under its own store brand or exclusive white-label formulation (not merely reselling a branded manufacturer drug like Ozempic or Wegovy), or operating a fully integrated telehealth-plus-dispensing program where the retailer's own pharmacy fulfills compounded or licensed GLP-1 medication under the retailer's own brand name. Programs that only refer customers to third-party telehealth providers without the retailer's own branded dispensing do NOT qualify. The launch must be confirmed by a company press release, an SEC filing (8-K or 10-K), or a report in Reuters, Bloomberg, Wall Street Journal, or CNBC, published before December 31, 2026. If two or more retailers launch on the same calendar date, this resolves to 'None of the above.' If no qualifying launch occurs before December 31, 2026, this resolves to 'None of the above.'

Source: https://www.wsj.com/business/retail

Resolves by Feb 27, 2027.